Jag Capital Management LLC Takes $13.76 Million Position in Gilead Sciences, Inc. $GILD

Jag Capital Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The institutional investor bought 112,101 shares of the biopharmaceutical company’s stock, valued at approximately $13,759,000. Gilead Sciences comprises about 1.5% of Jag Capital Management LLC’s holdings, making the stock its 27th biggest holding.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. grew its position in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after buying an additional 7,168 shares during the period. iA Global Asset Management Inc. grew its position in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after buying an additional 23,046 shares during the period. Sector Gamma AS grew its position in shares of Gilead Sciences by 15.9% during the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after buying an additional 20,239 shares during the period. Finally, NewEdge Wealth LLC grew its position in shares of Gilead Sciences by 2.9% during the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after buying an additional 17,284 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target for the company. Barclays assumed coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target for the company. Cantor Fitzgerald lowered their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 10th. Weiss Ratings upgraded shares of Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, May 11th. Finally, Truist Financial reiterated a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $156.62.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 63,000 shares of company stock valued at $8,523,570. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 0.6%

Shares of NASDAQ:GILD opened at $130.50 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market capitalization of $162.02 billion, a PE ratio of 17.78 and a beta of 0.31. The company has a 50 day moving average price of $137.18 and a two-hundred day moving average price of $133.48.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead was highlighted in a hedge-fund screen as one of the “best long-term low-risk stocks,” which may reinforce the view that institutional investors see it as a relatively defensive large-cap healthcare name. 5 Best Long Term Low Risk Stocks to Buy According to Hedge Funds
• Positive Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference, keeping investor focus on Gilead’s HIV, oncology, and pipeline outlook following its recent earnings beat. Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Positive Sentiment: Daiwa Securities lowered its price target to $150 from $161 but kept an Outperform rating, suggesting the firm still sees upside from current levels despite the cut.
• Positive Sentiment: Recent commentary around Gilead’s Q1 results pointed to solid execution, including strong HIV franchise performance and momentum in oncology, which supports the stock’s valuation. Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
• Neutral Sentiment: Gilead’s CFO and another senior insider disclosed stock sales, but both were made under pre-arranged 10b5-1 plans, which limits the bearish signal. Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock
• Negative Sentiment: Despite the constructive backdrop, analyst target cuts and insider selling may be creating some caution and helping cap gains in the near term.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.